Marksans Pharma Limited (MARKSANS.BO)
INR 314.2
(-2.1%)
INR 314.2
(-2.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.8 Billion INR | 22.4% |
| 2022 | 21.9 Billion INR | 33.55% |
| 2021 | 16.4 Billion INR | 33.47% |
| 2020 | 12.28 Billion INR | 36.13% |
| 2019 | 9.02 Billion INR | 12.31% |
| 2018 | 8.03 Billion INR | 9.77% |
| 2017 | 7.32 Billion INR | -2.61% |
| 2016 | 7.51 Billion INR | 4.42% |
| 2015 | 7.19 Billion INR | 6.58% |
| 2014 | 6.75 Billion INR | 37.84% |
| 2013 | 4.9 Billion INR | 22.14% |
| 2012 | 4.01 Billion INR | 4.2% |
| 2011 | 3.85 Billion INR | -21.72% |
| 2010 | 4.91 Billion INR | -23.81% |
| 2009 | 6.45 Billion INR | 2.53% |
| 2008 | 6.29 Billion INR | 14.21% |
| 2007 | 5.51 Billion INR | 12.42% |
| 2006 | 4.9 Billion INR | 5.03% |
| 2005 | 4.66 Billion INR | 98.7% |
| 2004 | 2.34 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 23.13 Billion INR | 0.0% |
| 2023 FY | 26.8 Billion INR | 22.4% |
| 2023 Q4 | 26.8 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 21.9 Billion INR | 0.0% |
| 2022 FY | 21.9 Billion INR | 33.55% |
| 2022 Q2 | 16.68 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q4 | 16.4 Billion INR | 0.0% |
| 2021 Q2 | 14.07 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 16.4 Billion INR | 33.47% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 10.53 Billion INR | 0.0% |
| 2020 Q4 | 12.28 Billion INR | 0.0% |
| 2020 FY | 12.28 Billion INR | 36.13% |
| 2019 FY | 9.02 Billion INR | 12.31% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 8.07 Billion INR | 0.0% |
| 2019 Q4 | 9.02 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 8.03 Billion INR | 9.77% |
| 2018 Q2 | 7.69 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 8.03 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 7.32 Billion INR | -2.61% |
| 2017 Q4 | 7.32 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 8.6 Billion INR | 0.0% |
| 2016 FY | 7.51 Billion INR | 4.42% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 6.88 Billion INR | 0.0% |
| 2016 Q4 | 7.51 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 7.19 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 7.29 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 7.19 Billion INR | 6.58% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 6.75 Billion INR | 21.66% |
| 2014 Q3 | 5.55 Billion INR | 4.81% |
| 2014 Q2 | 5.29 Billion INR | 0.0% |
| 2014 FY | 6.75 Billion INR | 37.84% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 4.38 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 4.9 Billion INR | 0.0% |
| 2013 FY | 4.9 Billion INR | 22.14% |
| 2012 FY | 4.01 Billion INR | 4.2% |
| 2012 Q2 | 8.14 Billion INR | 0.0% |
| 2012 Q4 | 4.01 Billion INR | 0.0% |
| 2011 FY | 3.85 Billion INR | -21.72% |
| 2010 FY | 4.91 Billion INR | -23.81% |
| 2009 FY | 6.45 Billion INR | 2.53% |
| 2008 FY | 6.29 Billion INR | 14.21% |
| 2007 FY | 5.51 Billion INR | 12.42% |
| 2006 FY | 4.9 Billion INR | 5.03% |
| 2005 FY | 4.66 Billion INR | 98.7% |
| 2004 FY | 2.34 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Abbott India Limited | 51.93 Billion INR | 48.379% |
| Cipla Limited | 327.17 Billion INR | 91.806% |
| Gland Pharma Limited | 106.61 Billion INR | 74.853% |
| GlaxoSmithKline Pharmaceuticals Limited | 35.73 Billion INR | 24.982% |
| Kopran Limited | 7.43 Billion INR | -260.709% |
| NGL Fine-Chem Limited | 3.55 Billion INR | -654.06% |
| Pfizer Limited | 42.28 Billion INR | 36.602% |
| Sanofi India Limited | 17.14 Billion INR | -56.342% |
| SMS Pharmaceuticals Limited | 10.34 Billion INR | -159.257% |